Skip to content
Disclosery

Venrock Adviser, LLC

Follow

13F filer, CIK 1615982, NEW YORK, NY

Venrock Adviser, LLC reported $1,776,690,536 across 33 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14. Its ten largest share positions make up 69.03% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001615982-25-000006

Period
2025-09-30
Reported value
$1.78B
Holdings
33
Top 10 weight
69.03%
New
2
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MAZEnew+1,230,769$31.9M
CDTXadded+307,700$29.5M
VORnew+499,966$24.4M
SVRAadded+3,796,780$13.6M
CTMXadded+1,591,618$5.08M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ABVXreduced-769,051-$65.3M
PHVSreduced-1,373,021-$34.3M
UPBreduced-1,126,021-$21.2M
ELVNreduced-800,000-$16.4M
COGTreduced-755,411-$10.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001615982-25-000006, largest first. % of portfolio is the value over $1,776,690,536, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 8,493,321 shares; 2024Q4: 8,493,321 shares; 2025Q1: 8,493,321 shares; 2025Q2: 8,493,321 shares; 2025Q3: 8,493,321 shares 8,493,321$337M18.99%0Timeline
MTSRMETSERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 3,750,662 shares; 2025Q2: 3,750,662 shares; 2025Q3: 3,750,662 shares 3,750,662$196M11.05%0Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 12,762,462 shares; 2024Q4: 12,762,462 shares; 2025Q1: 12,762,462 shares; 2025Q2: 12,762,462 shares; 2025Q3: 13,161,462 shares 13,161,462$154M8.66%+399,000Timeline
CDTXCIDARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 765,723 shares; 2025Q1: 1,051,518 shares; 2025Q2: 639,088 shares; 2025Q3: 946,788 shares 946,788$90.7M5.1%+307,700Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,882,709 shares; 2024Q4: 3,882,709 shares; 2025Q1: 3,882,709 shares; 2025Q2: 3,882,709 shares; 2025Q3: 3,882,709 shares 3,882,709$83.8M4.72%0Timeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,249,731 shares; 2024Q4: 6,249,731 shares; 2025Q1: 6,703,985 shares; 2025Q2: 6,728,985 shares; 2025Q3: 6,728,985 shares 6,728,985$82M4.61%0Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,085,620 shares; 2024Q4: 3,285,620 shares; 2025Q1: 4,148,428 shares; 2025Q2: 4,148,428 shares; 2025Q3: 4,148,428 shares 4,148,428$79.8M4.49%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,394,527 shares; 2024Q4: 4,394,527 shares; 2025Q1: 3,182,527 shares; 2025Q2: 6,596,885 shares; 2025Q3: 6,596,885 shares 6,596,885$79.2M4.46%0Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,026,331 shares; 2024Q4: 4,026,331 shares; 2025Q1: 4,026,331 shares; 2025Q2: 4,026,331 shares; 2025Q3: 3,226,331 shares 3,226,331$66M3.72%-800,000Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 5,684,167 shares; 2024Q4: 5,684,411 shares; 2025Q1: 5,684,411 shares; 2025Q2: 4,755,411 shares; 2025Q3: 4,000,000 shares 4,000,000$57.4M3.23%-755,411Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,969,882 shares; 2025Q3: 15,561,500 shares 15,561,500$49.6M2.79%+1,591,618Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,345,780 shares; 2024Q4: 1,345,780 shares; 2025Q1: 1,345,780 shares; 2025Q2: 1,345,780 shares; 2025Q3: 576,729 shares 576,729$49M2.76%-769,051Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 3,257,639 shares; 2025Q2: 8,884,263 shares; 2025Q3: 12,681,043 shares 12,681,043$45.3M2.55%+3,796,780Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,685,448 shares; 2024Q4: 2,685,448 shares; 2025Q1: 2,685,448 shares; 2025Q2: 2,685,448 shares; 2025Q3: 2,685,448 shares 2,685,448$45M2.53%0Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 16,216,216 shares; 2024Q4: 16,216,216 shares; 2025Q1: 16,216,216 shares; 2025Q2: 17,857,083 shares; 2025Q3: 17,857,083 shares 17,857,083$38.9M2.19%0Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,744,373 shares; 2024Q4: 1,744,373 shares; 2025Q1: 1,744,373 shares; 2025Q2: 1,000,000 shares; 2025Q3: 960,803 shares 960,803$37.8M2.13%-39,197Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,565,841 shares; 2024Q4: 5,046,414 shares; 2025Q1: 5,046,414 shares; 2025Q2: 5,046,414 shares; 2025Q3: 5,046,414 shares 5,046,414$34.5M1.94%0Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,230,769 shares 1,230,769$31.9M1.8%newTimeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 3,220,364 shares; 2025Q3: 3,220,364 shares 3,220,364$27.8M1.56%0Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,173,913 shares; 2024Q4: 2,173,913 shares; 2025Q1: 2,173,913 shares; 2025Q2: 2,173,913 shares; 2025Q3: 2,173,913 shares 2,173,913$27.5M1.55%0Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 499,966 shares 499,966$24.4M1.37%newTimeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,295,319 shares; 2025Q1: 2,295,319 shares; 2025Q2: 2,295,319 shares; 2025Q3: 1,169,298 shares 1,169,298$22M1.24%-1,126,021Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,023,166 shares; 2024Q4: 2,023,166 shares; 2025Q1: 5,023,166 shares; 2025Q2: 4,631,216 shares; 2025Q3: 4,631,216 shares 4,631,216$20.1M1.13%0Timeline
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,458,645 shares; 2024Q4: 2,457,348 shares; 2025Q1: 2,457,348 shares; 2025Q2: 2,457,348 shares; 2025Q3: 2,457,348 shares 2,457,348$17.9M1.01%0
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,395,606 shares; 2024Q4: 3,220,130 shares; 2025Q1: 3,112,720 shares; 2025Q2: 2,047,620 shares; 2025Q3: 674,599 shares 674,599$16.8M0.95%-1,373,021Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,387,864 shares; 2025Q3: 1,387,864 shares 1,387,864$16.5M0.93%0Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 540,453 shares; 2025Q3: 610,808 shares 610,808$11.5M0.65%+70,355Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,379,965 shares; 2024Q4: 1,379,965 shares; 2025Q1: 1,379,965 shares; 2025Q2: 1,379,965 shares; 2025Q3: 1,379,965 shares 1,379,965$8.18M0.46%0Timeline
SRZNSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 632,931 shares; 2025Q2: 632,931 shares; 2025Q3: 632,931 shares 632,931$8.16M0.46%0Timeline
FRNMPERCEPTIVE CAP SOLUTIONS CORQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 750,000 shares; 2024Q4: 750,000 shares; 2025Q1: 750,000 shares; 2025Q2: 750,000 shares; 2025Q3: 750,000 shares 750,000$7.95M0.45%0Timeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,609,569 shares; 2024Q4: 1,609,569 shares; 2025Q1: 1,609,569 shares; 2025Q2: 1,609,569 shares; 2025Q3: 1,609,569 shares 1,609,569$4.62M0.26%0Timeline
TENXTENAX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 208,333 shares; 2024Q4: 208,333 shares; 2025Q1: 208,333 shares; 2025Q2: 98,564 shares; 2025Q3: 437,708 shares 437,708$3.33M0.19%+339,144Timeline
CASIFCASI PHARMACEUTICALS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 987,259 shares; 2024Q4: 987,259 shares; 2025Q1: 987,259 shares; 2025Q2: 987,259 shares; 2025Q3: 987,259 shares 987,259$1.64M0.09%0Timeline

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001615982-25-000006 base2025-11-14acceptance time not in the bulk data set